What it claimed is

1. Pharmaceutical composition obtained from the green or mature fruits of *Roystonea regia*, which contains a mixture of the primary fatty acids with 8 to 28 carbon atoms, including the following fatty acids: caprilic (C8:0), capric (C10:0), lauric (C12:0), miristic (C14:0), palmitic (C16:0), palmitoleic (C16:1), estearic (C18:0) and oleic (C18:1) (which includes oleic acid itself, linoleic and linolenic acids), as well as a mixture of the esters of such fatty acids. The free fatty acids are enriched from the esters hydrolisis.

2. Pharmaceutical composition which contains a mixture of the primary fatty acids and the esters thereof, according to the claim 1, characterized by the following composition in fatty acids

Mixture of fatty acids present in the lipid extract of *Roystonea regia* fruits

Caprylic acid (C8:0)	< 3.0
Capric acid (C10:0)	< 3.0
Lauric acid (C12:0)	3.0 - 40.0 %
Miristic acid (C14:0)	4.0 - 15.0 %
Palmitic acid (C16:0)	10.0 - 80.0 %
Palmitoleic acid (C16:1)	1.5 - 20.0 %
Estearic acid (C18:0)	0.1 - 5.0 %
Oleic acid (C18:1)	3.0 - 50.0 %

3. Pharmaceutical composition containing a mixture of fatty acids according to claims 1 and 2 for the treatment of BPH, prostatitis, alopecia and hirsutism.

4. Method for the obtention of the pharmaceutical composition obtained from *Roystonea regia* according to the claim 1, 2 and 3 including the drying, ground and sieving of *Roystonea regia* fruits, and a further separation of the extract from other

components through a solid/liquid extraction in organic solvents like hydrocarbons of 5 to 8 carbon atoms, alcohols of 1 to 3 carbon atoms, as well as mixture of them, with or without a previous basic hydrolysis using hydroxides or alkalis.

5. Method of obtention according to the claim 4, including the drying of *Roystonea regia* fruits at a temperature between 10 and 100 ^{0}C for a time ranging from 1 to 1000 hours, and further ground in a proper mill, that allow obtain a particle size < 6000 μm. The time for the extraction of the components of the active extract ranges from 1 to 50 h and the temperature from 0 to 70 ^{0}C.

6. Method of obtention according to the claim 4 and 5, characterized by the use of alkaline- hydroxides or alkaline-earthen hydroxides and organic for the basic hydrolisis, especifically those of low molecular weight and more specifically sodium, potassium, calcium or ammonium hydroxides.

7. Method of obtention according to the claim 4 and 5, characterized by the use of hydrocarbons like pentane, hexane, heptane or octane for the obtention of the extract containing the mixture of fatty acids.

8. Method of obtention according to the claim 4 and 5, characterized by the use of alcohols like methanol, ethanol, n-propanol y 2-propanol for the obtention of the extract containing the mixture of fatty acids.

9. Pharmaceutical composition as per the claims 1, 2 and 3 to be used as medication in the treatment of BPH, prostatitis, alopecia and hirsutism.

10. Pharmaceutical composition with or without a saponification, as per the claims 1 and 2, characterized by its use in the treatment and or to prevent BPH, prostatitis, alopecia and hirsutism.

11. Pharmaceutical composition as per the claims 1, 2 and 3 to be used as medication in the treatment of BPH, prostatitis, alopecia and hirsutism.

12. Pharmaceutical composition with or without a saponification, as per the claims 1, 2 and 3 characterized by its use in the treatment and/or to prevent BPH, prostatitis, alopecia and hirsutism.

13. Pharmaceutical composition with or without a saponification, as per the claims 1, 2, 3, 10, 11 and 12, characterized by its use, at daily doses from 50 to 1000 mg, specifically formulated at doses between 150 and 1000 mg, to be administered as solid oral forms (capsules, soft-gel capsules, tablets) or liquids (emulsions), as supossitories or like tinctures, lotions or shampoos of local action in the treatment and/or prevention of BPH, prostatitis, alopecia and hirsutism.